Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus

Antiviral Res. 2014 Jan:101:57-61. doi: 10.1016/j.antiviral.2013.10.014. Epub 2013 Nov 1.

Abstract

Cytomegalovirus (CMV) strains resistant to ganciclovir, cidofovir and/or foscarnet were genotypically and phenotypically characterised in two haematopoietic stem cell transplant recipients and three solid-organ transplant recipients with CMV disease. The anti-malaria drug artesunate led to a favourable virological and clinical response in three cases with mild CMV diseases (fever and neutropaenia) but was ineffective in two fatal CMV diseases with lung involvement in spite of a decrease in the CMV DNA load in blood and bronchoalveolar fluid.

Trial registration: ClinicalTrials.gov NCT01008540.

Keywords: Artesunate; Cytomegalovirus; Multidrug resistance; Transplantation.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Artemisinins / therapeutic use*
  • Artesunate
  • Cytomegalovirus / drug effects*
  • Cytomegalovirus / genetics
  • Cytomegalovirus / isolation & purification
  • Cytomegalovirus Infections / drug therapy*
  • Cytomegalovirus Infections / virology
  • Drug Resistance, Viral*
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Organ Transplantation / adverse effects
  • Transplantation
  • Treatment Outcome
  • Viral Load

Substances

  • Antiviral Agents
  • Artemisinins
  • Artesunate

Associated data

  • ClinicalTrials.gov/NCT01008540